India, July 30 -- French drug major Sanofi SA (SNY,SNYNF,SAN.PA) reported Thursday sharply lower net profit in its second quarter, while business earnings climbed from last year with strong sales growth. Further, the firm upgraded its fiscal 2026 outlook.
For fiscal 2026, the pharmaceutical company now expects sales to grow approximately 10 percent at constant exchange rates in 2026, with business earnings per share projected to expand slightly faster than sales.
The company previously expected sales to grow by a high single-digit percentage and business earnings per share to grow slightly faster than sales, at constant exchange rates.
In the second quarter, net income attributable to equity holders of Sanofi was €343 million, shar...